Evkeeza (evinacumab-dgnb) / Regeneron, Ultragenyx - LARVOL DELTA

Evolocumab for high cardiovascular risk patients without previous stroke: a network meta-analysis of randomized controlled trials (ESC 2026) - "Purpose: To investigate the efficacy and safety of non-statin treatments—including evolocumab, alirocumab, enlicitide, inclisiran, evinacumab, omega-3 fatty acids, and ezetimibe—in high CV risk patients without previous stroke. Evolocumab had the potential to be the first-line non-statin option for high CV risk patients without previous stroke due to its efficacy in reducing MACE, CV mortality, LDL-C, and Lp(a)."

Retrospective data • Cardiovascular • Dyslipidemia • Myocardial Infarction

Familial Hypercholesterolemia. (PubMed, Methodist Debakey Cardiovasc J) - "Prompt recognition and treatment with statins, often combined with ezetimibe, modifies the natural course of the disease...In statin-intolerant patients, bempedoic acid may provide additional therapeutic options. The most severe form, homozygous FH (HoFH), has an estimated prevalence of ~1 in 367,000 individuals and is associated with ASCVD in youth, calcific aortic stenosis, and a markedly reduced life expectancy. Patients with HoFH require specialized care and may need LDL apheresis and specific orphan drugs such as lomitapide or evinacumab."

Biomarker • Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Homozygous Familial Hypercholesterolemia • Metabolic Disorders • APOB

Evinacumab Across Different Lipid Phenotypes: A Systematic Review and Meta-Analysis. (PubMed, Adv Ther) - "Evinacumab provides substantial and sustained lipid-lowering effects, particularly in homozygous familial hypercholesterolemia. Emerging evidence also supports a potential role in severe hypertriglyceridemia, although further studies are needed to define its clinical benefits in this setting."

Journal • Retrospective data • Dyslipidemia • Familial Chylomicronemia Syndrome • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Hypertriglyceridemia • Metabolic Disorders • Severe Hypertriglyceridemia • ANGPTL3 • APOB

ANCHOR-POC: Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease (clinicaltrials.gov) - P2 | N=195 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Trial completion date: Apr 2028 ➔ Oct 2028 | Trial primary completion date: Sep 2027 ➔ Oct 2028

Trial completion date • Trial primary completion date • Diabetic Nephropathy • Nephrology • Renal Disease • APOB

Post-Marketing Safety Surveillance of Evinacumab Using the FDA Adverse Event Reporting System (AHA 2026) - "Abstract is embargoed at this time."

Adverse events • Clinical • P4 data

Effectiveness of Evinacumab in the Treatment of Homozygous Familial Hypercholesterolaemia: Single-Arm Meta-Analysis (AHA 2026) - "Abstract is embargoed at this time."

Retrospective data • Dyslipidemia • Familial Hypercholesterolemia • Homozygous Familial Hypercholesterolemia

Lipoprotein apheresis: still needed in many patients, or soon a historical practice? (PubMed, Clin Kidney J) - "An opposing view argues that modern and emerging pharmacological agents-PCSK9 inhibitors, inclisiran, bempedoic acid, evinacumab, and targeted Lp(a)-lowering antisense and small interfering RNA agents-have already rendered LA obsolete in almost all patients, with its remaining niche closing rapidly as outcome data accumulate. This combined manuscript juxtaposes the two positions in a streamlined form and concludes with a balanced conclusion of the future role of LA."

Journal • Review • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Familial Hypercholesterolemia • Heart Failure • Homozygous Familial Hypercholesterolemia • Peripheral Arterial Disease

Clinical Benefits Associated With Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia. (PubMed, J Am Heart Assoc) - "Add-on evinacumab increased number of children with homozygous familial hypercholesterolemia reaching and maintaining LDL-C goal, concomitant reduction in LA frequency, and in most patients, stabilization or improvement in coronary computed tomography angiography findings."

Journal • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders • Pediatrics • ANGPTL3

Evkeeza revenue in the second quarter 2026 was $21 million, driven by increased demand from new country launches and early access. (Financial Times)

Sales • Homozygous Familial Hypercholesterolemia

Evinacumab Treatment of Homozygous Familial Hypercholesterolemia Patients in a Real-World Setting: An Overview After the First Year of Therapy. (PubMed, AACE Endocrinol Diabetes) - "No side effects were observed, except for a suspected allergic reaction. Evinacumab on top of the best standard of care treatment is an effective treatment to further reduce LDL-C levels in HoFH patients."

Journal • Real-world evidence • Allergy • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders • ANGPTL3

Homozygous familial hypercholesterolemia, experience with Evinacumab treatment in two Mexican pediatric patients: case report. (PubMed, Front Genet) - "Serial vascular imaging in one patient revealed partial regression of subclavian and carotid artery stenosis, as well as reduced aortic wall thickening following sustained LDL-C reduction; adding evidence to the recently described vascular improvement associated with Evinacumab therapy in pediatric HoFH. Both patients also experienced clinically meaningful improvements in quality of life, and treatment was well tolerated without serious adverse events."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders • Pediatrics • ANGPTL3

Extracellular Vesicles as Biomarkers in Familial Hypercholesterolaemia Treated with Evinacumab. (ISTH 2026) - "Moreover, these findings support the potential role of EVs as dynamic biomarkers of disease activity and therapeutic response in FH. DOI*10.1016/j.rpth.2026.106333"

Biomarker • Atherosclerosis • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Inflammation • ANXA5 • APOB • CD14 • GYPA • ITGA2B • PTPRC • SELP

Efficacy and Safety of Evinacumab in Japanese Patients with Homozygous Familial Hypercholesterolemia: Long-term Results from an Open-label, Single-arm, Phase 3 Trial. (PubMed, J Atheroscler Thromb) - "Evinacumab treatment resulted in sustained reductions in LDL-C and other lipid parameters in Japanese patients ≥ 12 years with HoFH, including those undergoing lipoprotein apheresis, and was generally well tolerated."

Journal • P3 data • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders • ANGPTL3

Management of autosomal recessive hypercholesterolemia in a patient with an LDLRAP1 mutation. (PubMed, J Clin Lipidol) - "Achieving adequate LDL-C control for this patient required stepwise escalation of the lipid-lowering therapy comprising high-intensity statin therapy, proprotein convertase subtilisin/kexin type 9 inhibitor, bempedoic acid, and ultimately evinacumab. This case draws attention to the importance of appropriately diagnosing and treating individuals with ARH and initiating combination lipid-lowering therapy, including specialty medications indicated for this diagnosis, to effectively treat this disorder, as well as the importance of screening for valvular heart disease in this population."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Heart Failure • Homozygous Familial Hypercholesterolemia • Metabolic Disorders • LDLR

Unlocking Lipoprotein Lipase by Inhibiting the ANGPTL3 Brake (ENDO 2026) - "Reintroduction of alirocumab combined with evinacumab resulted in improved lipid levels: total cholesterol 129 mg/dL, TG 63 mg/dL (an 87% reduction from baseline), HDL-C 45 mg/dL, and LDL-C 72 mg/dL. While a sustained LDL-C increase was observed in our case, prompting reinitiated PCSK9 inhibitor therapy, clinical trial data suggest that LDL-C increase during severe hypertriglyceridemia treatment with ANGPTL3 inhibitors is expected and often transient. Intensification of statin and/or PCSK9 inhibitor therapy is recommended when LDL-C levels persist above therapeutic goals."

Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Diabetes • Dyslipidemia • Familial Chylomicronemia Syndrome • Genetic Disorders • Hypertriglyceridemia • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Pancreatitis • Respiratory Diseases • Severe Hypertriglyceridemia • Sleep Disorder • ANGPTL3 • LPL

Translating Lipoprotein Genetics Into New Therapies. (PubMed, Circ Res) - "This approach has driven approvals across multiple mechanistic classes targeting PCSK9 (proprotein convertase subtilisin/kexin type 9; low-density lipoprotein cholesterol lowering with demonstrated cardiovascular benefit), APOC3 (apolipoprotein C-III; olezarsen and plozasiran, both approved for triglyceride lowering in familial chylomicronemia syndrome), and ANGPTL3 (angiopoietin-like protein 3, evinacumab, approved for homozygous familial hypercholesterolemia), while Mendelian randomization prospectively identified HDL (high-density lipoprotein) cholesterol as a noncausal biomarker, predicting the failure of HDL-raising therapy in outcomes trials. Gene-editing approaches now extend this logic toward potentially permanent intervention. Genome-wide association studies and polygenic risk scores have expanded the landscape of candidate targets but have yet to achieve translational yield comparable to rare-variant genetics."

Journal • Review • Cardiovascular • Dyslipidemia • Familial Chylomicronemia Syndrome • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders • ANGPTL3

Drugs for hypercholesterolemia. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dyslipidemia • Metabolic Disorders

Homozygous familial hypercholesterolemia (HoFH) in Canada. (PubMed, Atherosclerosis) - "This analysis provides valuable insights into the evolving clinical profile of patients with HoFH across Canada. Despite advances in treatment, a significant proportion of patients continue to experience major cardiovascular events, underscoring the need for early diagnosis, aggressive lipid-lowering management, and equitable access to evidence-based therapies to optimize long-term outcomes and improve survival in this population."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders • Rare Diseases

New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering. (PubMed, Circ Res) - "Most established therapies that reduce major cardiovascular events, including statins, ezetimibe, PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, and bempedoic acid, act primarily by enhancing LDL receptor-mediated clearance of apoB-containing particles...Lomitapide, an inhibitor of MTP (microsomal triglyceride transfer protein), and evinacumab, a monoclonal antibody targeting ANGPTL3 (angiopoietin-like protein 3), reduce LDL cholesterol in homozygous familial hypercholesterolemia by decreasing triglyceride-rich apoB-containing lipoproteins upstream of LDL particle formation...Gene-targeted approaches, including gene editing, epigenome editing, small interfering RNA, and antisense oligonucleotides, as well as novel oral or injectable agents and combination therapies, further broaden opportunities for durable apoB modulation. Transitioning from an LDL cholesterol-centric to an apoB-centric framework may represent a biologically integrated strategy to..."

Clinical • Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Severe Hypertriglyceridemia • ANGPTL3 • APOB

Current and Future Perspectives of LDL-C Lowering Therapies 2026. (PubMed, J Atheroscler Thromb) - "Non-statin therapies, including ezetimibe, bile acid sequestrants, PCSK9 inhibitors, inclisiran, and bempedoic acid, are reviewed with an emphasis on their mechanisms, efficacy, and clinical positioning. Advanced therapies for severe dyslipidemia, such as lipoprotein apheresis, lomitapide, and evinacumab, are also discussed in this review...Collectively, these developments offer new opportunities to address unmet clinical needs, particularly in patients with FH, statin intolerance, and residual cardiovascular risk. A comprehensive understanding of these therapies is essential for further reducing the burden of ASCVD in the coming decades."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Metabolic Disorders

Targeting triglycerides for cardiovascular risk reduction. (PubMed, Intern Emerg Med) - "By contrast, icosapent ethyl, a highly purified ethyl ester of eicosapentaenoic acid, is the only TRL-targeted therapy that has demonstrated a significant reduction in major cardiovascular events in a large, randomized trial, irrespective of baseline triglyceride levels. Novel agents such as evinacumab (an ANGPTL3 monoclonal antibody) and antisense oligonucleotides against apolipoprotein C-III (volanesorsen, olezarsen, plozasiran) have produced marked decreases in triglycerides, apoB-containing lipoproteins and remnant cholesterol in recent clinical studies, even though cardiovascular outcome data are not yet available. Therefore, therapies targeting TRL metabolism represent a promising approach to reduce residual cardiovascular risk, particularly in high-risk or statin-treated patients."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Hypertriglyceridemia • ANGPTL3 • APOB

UTILIZATION, EXPENDITURE, AND PRICE TRENDS FOR EZETIMIBE AND NOVEL LIPID-LOWERING MEDICATIONS IN U.S. MEDICAID DRUG UTILIZATION DATA, 2002-2024 (ISPOR 2026) - "The analysis included ezetimibe (Zetia® and generic), and novel lipid-lowering medications: evolocumab (Repatha®), alirocumab (Praluent®), inclisiran (Leqvio®), bempedoic acid (Nexletol®), and evinacumab (Evkeeza®). Despite continued dominance of ezetimibe in prescription volume, Medicaid spending has shifted substantially toward high-cost NLLMs. These findings highlight a growing divergence between utilization and expenditure in Medicaid drug spending and underscore the importance of value-based pricing, outcomes-linked contracting, and formulary strategies as adoption of novel lipid-lowering agents expands."

Medicaid • Reimbursement • US reimbursement • ANGPTL3

Promise of ANGPTL3 as a therapeutic target for controlling cholesterol levels. (PubMed, Expert Opin Ther Targets) - "These observations rapidly catalyzed the development of pharmacologic strategies to inhibit ANGPTL3 using monoclonal antibodies (e.g. evinacumab), antisense oligonucleotides (e.g. vupanorsen), small interfering ribonucleic acid (e.g. zodasiran and solbinsiran), and most recently genome-editing approaches (e.g. VERVE-201 and CTX310). The degree of hypertriglyceridemia in the patient's baseline lipid profile appears to be an important determinant of drug response. Drawing on genetic, mechanistic, and clinical trial data, the promise and limitations of ANGPTL3 inhibition are considered and its potential place in future lipid-lowering strategies is outlined."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Hypertriglyceridemia • Metabolic Disorders • ANGPTL3

EVOLVE-HoFH: Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) (clinicaltrials.gov) - P=N/A | N=52 | Recruiting | Sponsor: Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) | Not yet recruiting ➔ Recruiting

Enrollment open • Real-world evidence • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders

Evkeeza revenue in the first quarter 2026 was $18 million, driven by increased demand from new country launches and early access. (GlobeNewswire)

Sales • Cardiovascular • Homozygous Familial Hypercholesterolemia